Fruquintinib plus best supportive care for patients with metastatic colorectal cancer: Characterization of patients who had an overall survival of ≥10 months in the FRESCO-2 study.

Stefan Kasper, François Ghiringhelli, Violaine Randrian et al.|Journal of Clinical Oncology|2025

Cited by 0